arv-trials.com — where HIV science happens first
Live coverage of the world’s leading HIV congresses.
Expert insights. Sharp analysis. Real impact.
Tune in live. Download the key slides.
Stay ahead. Stay informed.
Previous international meetings webinars:
Previous thematic webinars:
>
TYPE OF ARV TRIALS
DRUGS
Head-to-head comparative trials for first line ART since 2006
Switch studies in virologically suppressed patients
Phase 2 of new ARVs
Switch studies in virologically suppressed patients
Switch ABC/3TC to TDF/FTC
Switch TDF to TAF
Switch PI to NNRTI
Switch NNRTI to NNRTI
Switch to DOR/3TC/TDF
Switch to ATV or ATV-r
Switch to PI/r reduced dose
Switch to PI/r monotherapy
Switch to RAL-containing regimen
Switch to DTG-containing regimen
Switch to E/C/FTC/TDF
Switch to E/C/F/TAF
Switch to E/C/F/TAF + DRV/r
Switch to BIC/FTC/TAF
Switch to INSTI + NNRTI
Switch to RAL + PI/r
Switch to PI/r + 3TC
Switch to DRV/r + RPV
Switch to D/C/F/TAF
Switch to MVC
Phase 2 of new ARVs
Fostemsavir, prodrug of temsavir (attachment inhibitor)
TAF (TFV prodrug)
Doravirine (non nucleoside reverse transcriptase inhibitor)
Cabotegravir (integrase inhibitor)
Bictegravir
Islatravir (ISL)
VIEW STUDIES (140)
Search by study name
Une édition AEI
AEI, agence d'édition spécialisée dans la santé et le digital
52 rue de la Fédération 75015 - Paris - Tél. : 01 45 79 03 04
CPPAP n° 0921 W 93318
Responsable des éditions :
Charles Dufrene
>
